Q3 2024
|
84 |
423,312 |
XBI, STXS, RVMD, CYTK
|
13F-HR
|
11/14/2024 |
000138993224000020 |
Q2 2024
|
83 |
418,567 |
XBI, STXS, MRUS, CYTK
|
13F-HR
|
8/14/2024 |
000138993224000016 |
Q1 2024
|
72 |
439,278 |
XBI, STXS, CYTK, IDYA
|
13F-HR
|
5/15/2024 |
000138993224000012 |
Q4 2023
|
76 |
417,341 |
XBI, CYTK, STXS, IDYA
|
13F-HR
|
2/14/2024 |
000138993224000004 |
Q3 2023
|
75 |
321,489 |
XBI, STXS, CYTK, IDYA
|
13F-HR
|
11/14/2023 |
000138993223000010 |
Q2 2023
|
73 |
365,729 |
XBI, ISEE, STXS, BPMC
|
13F-HR
|
8/14/2023 |
000138993323000008 |
Q1 2023
|
72 |
333,536 |
XBI, STXS, ISEE, ASND
|
13F-HR
|
5/15/2023 |
000138993323000006 |
Q4 2022
|
79 |
355,054 |
XBI, STXS, ASND, KRTX
|
13F-HR
|
2/14/2023 |
000138993323000002 |
Q3 2022
|
87 |
371,806 |
XBI, STXS, BPMC, BIOHAVEN PHARMACTL HLDG CO L
|
13F-HR
|
11/14/2022 |
000138993322000010 |
Q2 2022
|
90 |
366,898 |
XBI, STXS, BIOHAVEN PHARMACTL HLDG CO L, ACET
|
13F-HR
|
8/15/2022 |
000138993322000008 |
Q1 2022
|
94 |
383,776 |
STXS, XBI, FATE, BPMC
|
13F-HR
|
5/16/2022 |
000138993322000006 |
Q4 2021
|
87 |
397,677 |
STXS, BPMC, FATE, ACET
|
13F-HR
|
2/14/2022 |
000138993322000002 |
Q3 2021
|
80 |
376,924 |
STXS, BPMC, FATE, BIOHAVEN PHARMACTL HLDG CO L
|
13F-HR
|
11/15/2021 |
000138993321000011 |
Q2 2021
|
84 |
478,152 |
STXS, FATE, DRNA, BPMC
|
13F-HR
|
8/16/2021 |
000138993321000009 |
Q1 2021
|
89 |
421,480 |
STXS, FATE, BPMC, DRNA
|
13F-HR
|
5/17/2021 |
000138993321000007 |
Q4 2020
|
74 |
336,078 |
STXS, FATE, BPMC, SAGE
|
13F-HR
|
2/16/2021 |
000138993321000004 |
Q3 2020
|
80 |
307,632 |
STXS, IMMU, BPMC, FATE
|
13F-HR
|
11/16/2020 |
000138993320000010 |
Q2 2020
|
87 |
346,509 |
STXS, BPMC, FATE, ARNA
|
13F-HR
|
8/14/2020 |
000138993320000008 |
Q1 2020
|
80 |
239,627 |
STXS, BPMC, FATE, GLPG
|
13F-HR
|
5/15/2020 |
000138993320000006 |
Q4 2019
|
81 |
291,332 |
STXS, PRQR, ATRC, ARQL
|
13F-HR
|
2/14/2020 |
000138993320000004 |
Q3 2019
|
89 |
265,897 |
STXS, SAGE, ALDR, BPMC
|
13F-HR
|
11/14/2019 |
000138993319000010 |
Q2 2019
|
87 |
266,028 |
STXS, SAGE, BPMC, ATRC
|
13F-HR
|
8/14/2019 |
000138993319000008 |
Q1 2019
|
79 |
231,803 |
STXS, SAGE, BPMC, ATRC
|
13F-HR
|
5/15/2019 |
000138993319000006 |
Q4 2018
|
83 |
201,092 |
LOXO, STXS, SAGE, ATRC
|
13F-HR
|
2/14/2019 |
000138993319000002 |
Q3 2018
|
75 |
243,521 |
LOXO, STXS, SAGE, ATRC
|
13F-HR
|
11/14/2018 |
000138993318000012 |
Q2 2018
|
75 |
213,579 |
LOXO, SAGE, STXS, AERIE PHARMACEUTICALS INC
|
13F-HR
|
8/13/2018 |
000138993318000010 |
Q1 2018
|
75 |
205,558 |
LOXO, SAGE, STXS, BPMC
|
13F-HR
|
5/15/2018 |
000138993318000008 |
Q4 2017
|
72 |
185,688 |
LOXO, BPMC, ATRC, AERIE PHARMACEUTICALS INC
|
13F-HR
|
2/14/2018 |
000138993318000002 |
Q3 2017
|
73 |
161,052 |
LOXO, ATRC, 49BA.SG, IMMU
|
13F-HR
|
11/14/2017 |
000138993317000025 |
Q2 2017
|
75 |
140,138 |
LOXO, ATRC, IMMU, AERIE PHARMACEUTICALS INC
|
13F-HR
|
8/14/2017 |
000138993317000023 |
Q1 2017
|
72 |
118,230 |
LOXO, ATRC, NXSTAGE MEDICAL INC, ALDR
|
13F-HR
|
5/15/2017 |
000138993317000018 |
Q4 2016
|
66 |
113,823 |
ATRC, NXSTAGE MEDICAL INC, ALDR, LOXO
|
13F-HR
|
2/14/2017 |
000138993317000014 |
Q3 2016
|
74 |
143,580 |
VTAE, CYNA, ATRC, NXSTAGE MEDICAL INC
|
13F-HR
|
11/14/2016 |
000138993316000037 |
Q2 2016
|
94 |
126,173 |
NXSTAGE MEDICAL INC, ATRC, VTAE, DERM
|
13F-HR
|
8/15/2016 |
000138993316000031 |
Q1 2016
|
93 |
115,926 |
ATRC, ABBV, NXSTAGE MEDICAL INC, VTAE
|
13F-HR
|
5/16/2016 |
000138993316000029 |
Q4 2015
|
77 |
112,179 |
ATRC, NXSTAGE MEDICAL INC, ABBV, MRNS
|
13F-HR
|
2/12/2016 |
000138993316000022 |
Q3 2015
|
88 |
100,779 |
ATRC, ABBV, NXSTAGE MEDICAL INC, ZSPH
|
13F-HR
|
11/13/2015 |
000138993315000019 |
Q2 2015
|
75 |
118,236 |
ATRC, ABBV, NXSTAGE MEDICAL INC, ACHN
|
13F-HR
|
8/14/2015 |
000138993315000016 |
Q1 2015
|
71 |
130,246 |
PCYC, ATRC, ASPX, NXSTAGE MEDICAL INC
|
13F-HR
|
5/15/2015 |
000138993315000013 |
Q4 2014
|
62 |
126,410 |
PCYC, ATRC, ASPX, NXSTAGE MEDICAL INC
|
13F-HR
|
2/17/2015 |
000138993315000009 |
Q3 2014
|
59 |
99,148 |
PCYC, DISCOVERY LABORATORIES INC, ATRC, NXSTAGE MEDICAL INC
|
13F-HR
|
11/14/2014 |
000138993314000012 |
Q2 2014
|
49 |
105,516 |
AMPE, ATRC, PCYC, DISCOVERY LABORATORIES INC
|
13F-HR
|
8/14/2014 |
000138993314000010 |
Q1 2014
|
46 |
116,350 |
DISCOVERY LABORATORIES INC, PCYC, ATRC, AMPE
|
13F-HR
|
5/15/2014 |
000138993314000008 |
Q4 2013
|
47 |
97,156 |
DISCOVERY LABORATORIES INC, PCYC, ATRC, STXS
|
13F-HR
|
2/14/2014 |
000138993314000001 |